Royalty Pharma
RPRX
RPRX
282 hedge funds and large institutions have $12.2B invested in Royalty Pharma in 2022 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 107 increasing their positions, 81 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
4.4% more ownership
Funds ownership: 62.45% → 66.85% (+4.4%)
1% more funds holding
Funds holding: 278 → 282 (+4)
Holders
282
Holding in Top 10
10
Calls
$75.8M
Puts
$5.52M
Top Buyers
| 1 | +$709M | |
| 2 | +$326M | |
| 3 | +$87.8M | |
| 4 |
Invesco
Atlanta,
Georgia
|
+$82.7M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
+$67.5M |
Top Sellers
| 1 | -$342M | |
| 2 | -$84M | |
| 3 | -$73.7M | |
| 4 |
VCG
Vantage Consulting Group
Virginia Beach,
Virginia
|
-$70.5M |
| 5 |
Berkshire Hathaway
Omaha,
Nebraska
|
-$58.3M |